UNSPSC 51144014: Methylphenidate

This classification denotes a cns stimulant with the molecular formula C14H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 207ZZ9QZ49, chemically known as 2-piperidineacetic acid, .alpha.-phenyl-, methyl ester, hydrochloride but more generally known as methylphenidate, which bears US NIH Compound Identifier 4158. European Medicines Agency schedules Methylphenidate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08870MIG.

UNSPSC 51144014 Methylphenidate is a Commodity code that captures state and local procurement of controlled and non-controlled pharmaceutical products, though recent opportunities tagged under this code span a broader pharmaceutical and healthcare product mix than the code's nominal scope suggests. The actual work solicited under the code includes acquisition of naloxone and drug deactivation systems for public health initiatives, participation in direct-to-manufacturer prescription programs, and procurement of generic multi-source pharmaceuticals and over-the-counter products for distribution through state and local government health systems and cooperative purchasing networks. Issuing bodies range across state health and human services departments (Texas Health and Human Services Commission, Minnesota Department of Administration), county government health programs (Seminole County, Florida), and multistate cooperative purchasing alliances serving participating state and local jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) has emerged as a repeat buyer in this space, administering procurement across multiple state and local health facilities.

Recent activity concentrates in Texas, Minnesota, and Florida, with MMCAP's reach extending to Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County's IFB60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response date (delivered quarterly to the Seminole County Community Health Building), the Texas Health and Human Services Commission's RFI HHS0017013 for direct-to-manufacturer prescription program capabilities with an April 3, 2026 response date, and MMCAP's S1070000015802 RFP for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response date and an effective contract date of July 1, 2026. Contracts typically run two years with optional renewals; vendors must maintain cGMP and Drug Supply Chain Security Act compliance, carry specified insurance coverage, and comply with E-Verify and federal environmental regulations when FEMA funding is involved.